๐Ÿ‡จ๐Ÿ‡ฆ Ships from Canada ยท Free Shipping Over $300 ยท All Prices Include Tax
โ† All Products

Currently Unavailable

Enter your email to be notified when this product is available.

For in vitro laboratory research use only. Not for human consumption. All products are supplied strictly for in vitro laboratory research use only. Not drugs, foods, supplements, or cosmetics. Not evaluated by Health Canada or the FDA.
Dose per Vial
30mg
Sold As
Single vial
Form
Lyophilized powder
Storage
2โ€“8ยฐC
Price
$170 CAD

Triple agonist (GIP/GLP-1/glucagon). 30mg lyophilized powder per vial.

All compounds independently tested and verifiedLab results โ†’


Also Available

Other Doses

5mg10mg15mg20mg40mg50mg60mg

Research

Retatrutide


What It Is

Retatrutide is the triple threat โ€” it hits GIP, GLP-1, AND glucagon receptors all at once. It's the first triple agonist to reach large clinical trials. The glucagon piece is the game-changer: it ramps up your body's energy expenditure and forces your liver to burn more fat. Early trial data produced the highest weight loss numbers ever seen in a controlled study.

How It Works

Three receptors, three effects. GLP-1 kills your appetite and slows digestion. GIP improves fat cell metabolism and insulin handling. Glucagon โ€” the new addition โ€” tells your liver to burn fat for fuel and cranks up thermogenesis (heat production = calories burned). The glucagon component is why retatrutide may cause more weight loss than even tirzepatide โ€” it literally increases how many calories you burn at rest.

What The Research Shows

01

Phase 2 data showed up to 24.2% weight loss at 48 weeks at the highest dose โ€” the most ever recorded in a controlled obesity trial at publication.

02

Up to 86% of participants normalized their liver fat levels. That's an extraordinary result for fatty liver.

03

Currently in Phase 3 trials (TRIUMPH program). If results hold, this becomes the most potent weight loss compound available.

04

Side effects are similar to other GLP-1 drugs โ€” mostly GI (nausea, diarrhea), worst in the first weeks, improving with dose titration.

Sources

Triple-Hormone-Receptor Agonist Retatrutide for Obesity

Jastreboff AM et al. โ€” N Engl J Med, 2023 ยท PubMed

Information derived from published preclinical and clinical research. Provided for educational purposes only โ€” not medical advice.

Customer Reviews

  • Ryan K.โ˜…โ˜…โ˜…โ˜…โ˜…

    Customer service is top notch and fast delivery!

  • Jamieโ˜…โ˜…โ˜…โ˜…โ˜…

    Had my order confirmation instantly, shipping information within hours and product delivered in 2 business days.

  • Jessica T.โ˜…โ˜…โ˜…โ˜…โ˜…

    Great communication when a product came back in stock and even got a free bottle of bac water!

  • Sanjiv R.โ˜…โ˜…โ˜…โ˜…โ˜…

    Product quality is the best and had it delivered to my office within 72 hours of ordering.

See all reviews โ†’
For in vitro laboratory research use only. Not for human consumption. All products are supplied strictly for in vitro laboratory research use only. Not drugs, foods, supplements, or cosmetics. Not evaluated by Health Canada or the FDA. By purchasing, you confirm compliance with all applicable laws and regulations.